Literature DB >> 8662091

Alternatively spliced forms of human killer inhibitory receptors.

C Döhring1, J Samaridis, M Colonna.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8662091     DOI： 10.1007/bf02602590

Source DB:  PubMed          Journal:  Immunogenetics        ISSN： 0093-7711            Impact factor:   2.846


× No keyword cloud information.
  14 in total

1.  Killer cell inhibitory receptors specific for HLA-C and HLA-B identified by direct binding and by functional transfer.

Authors:  N Wagtmann; S Rajagopalan; C C Winter; M Peruzzi; E O Long
Journal:  Immunity       Date:  1995-12       Impact factor: 31.745

2.  Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells.

Authors:  M Colonna; J Samaridis
Journal:  Science       Date:  1995-04-21       Impact factor: 47.728

3.  A human killer inhibitory receptor specific for HLA-A1,2.

Authors:  C Döhring; D Scheidegger; J Samaridis; M Cella; M Colonna
Journal:  J Immunol       Date:  1996-05-01       Impact factor: 5.422

4.  Recruitment of tyrosine phosphatase HCP by the killer cell inhibitor receptor.

Authors:  D N Burshtyn; A M Scharenberg; N Wagtmann; S Rajagopalan; K Berrada; T Yi; J P Kinet; E O Long
Journal:  Immunity       Date:  1996-01       Impact factor: 31.745

Review 5.  Natural killer cell receptors specific for MHC class I molecules.

Authors:  M Colonna
Journal:  Curr Opin Immunol       Date:  1996-02       Impact factor: 7.486

6.  Tyrosine kinase-dependent activation of human NK cell functions upon stimulation through a 58-kDa surface antigen selectively expressed on discrete subsets of NK cells and T lymphocytes.

Authors:  I Melero; A Salmerón; M A Balboa; J Aramburu; M López-Botet
Journal:  J Immunol       Date:  1994-02-15       Impact factor: 5.422

7.  Molecular cloning of NKB1. A natural killer cell receptor for HLA-B allotypes.

Authors:  A D'Andrea; C Chang; K Franz-Bacon; T McClanahan; J H Phillips; L L Lanier
Journal:  J Immunol       Date:  1995-09-01       Impact factor: 5.422

8.  Tyrosine phosphorylation of a human killer inhibitory receptor recruits protein tyrosine phosphatase 1C.

Authors:  K S Campbell; M Dessing; M Lopez-Botet; M Cella; M Colonna
Journal:  J Exp Med       Date:  1996-07-01       Impact factor: 14.307

9.  Existence of both inhibitory (p58) and activatory (p50) receptors for HLA-C molecules in human natural killer cells.

Authors:  A Moretta; S Sivori; M Vitale; D Pende; L Morelli; R Augugliaro; C Bottino; L Moretta
Journal:  J Exp Med       Date:  1995-09-01       Impact factor: 14.307

10.  P58 molecules as putative receptors for major histocompatibility complex (MHC) class I molecules in human natural killer (NK) cells. Anti-p58 antibodies reconstitute lysis of MHC class I-protected cells in NK clones displaying different specificities.

Authors:  A Moretta; M Vitale; C Bottino; A M Orengo; L Morelli; R Augugliaro; M Barbaresi; E Ciccone; L Moretta
Journal:  J Exp Med       Date:  1993-08-01       Impact factor: 14.307
View more
  12 in total

1.  Cutting Edge: KIR3DS1, a gene implicated in resistance to progression to AIDS, encodes a DAP12-associated receptor expressed on NK cells that triggers NK cell activation.

Authors:  William H Carr; David B Rosen; Hisashi Arase; Douglas F Nixon; Jakob Michaelsson; Lewis L Lanier
Journal:  J Immunol       Date:  2007-01-15       Impact factor: 5.422

Review 2.  The CD94/NKG2 C-type lectin receptor complex: involvement in NK cell-mediated recognition of HLA class I molecules.

Authors:  M López-Botet; M Carretero; J Pérez-Villar; T Bellón; M Llano; F Navarro
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

3.  U5 monoclonal antibody identifies a novel lymphocyte surface antigen preferentially expressed in human circulating natural killer cells with high cytotoxic activity.

Authors:  S Ikura; K Terao; I Matsuzaki; M Inoue-Murayama; Y Murayama
Journal:  Immunology       Date:  1999-03       Impact factor: 7.397

4.  Killer-cell immunoglobulin-like receptor (KIR) nomenclature report, 2002.

Authors:  Steven G E Marsh; Peter Parham; Bo Dupont; Daniel E Geraghty; John Trowsdale; Derek Middleton; Carlos Vilches; Mary Carrington; Campbell Witt; Lisbeth A Guethlein; Heather Shilling; Christian A Garcia; Katharine C Hsu; Hester Wain
Journal:  Immunogenetics       Date:  2003-06-28       Impact factor: 2.846

5.  Extracellular domain alterations impact surface expression of stimulatory natural killer cell receptor KIR2DS5.

Authors:  Noriko K Steiner; Sivanesan Dakshanamurthy; Christopher J VandenBussche; Carolyn K Hurley
Journal:  Immunogenetics       Date:  2008-08-06       Impact factor: 2.846

6.  Dramatically reduced surface expression of NK cell receptor KIR2DS3 is attributed to multiple residues throughout the molecule.

Authors:  C J VandenBussche; T J Mulrooney; W R Frazier; S Dakshanamurthy; C K Hurley
Journal:  Genes Immun       Date:  2008-11-13       Impact factor: 2.676

7.  Nature of allelic sequence polymorphism at the KIR3DL3 locus.

Authors:  Des C Jones; Susan E Hiby; Ashley Moffett; John Trowsdale; Neil T Young
Journal:  Immunogenetics       Date:  2006-07-06       Impact factor: 3.330

8.  The leukocyte receptor complex in chicken is characterized by massive expansion and diversification of immunoglobulin-like Loci.

Authors:  Katja Laun; Penny Coggill; Sophie Palmer; Sarah Sims; Zemin Ning; Jiannis Ragoussis; Emanuela Volpi; Natalie Wilson; Stephan Beck; Andreas Ziegler; Armin Volz
Journal:  PLoS Genet       Date:  2006-05-12       Impact factor: 5.917

9.  KIR2DS5 allotypes that recognize the C2 epitope of HLA-C are common among Africans and absent from Europeans.

Authors:  Jeroen H Blokhuis; Hugo G Hilton; Lisbeth A Guethlein; Paul J Norman; Neda Nemat-Gorgani; Annettee Nakimuli; Olympe Chazara; Ashley Moffett; Peter Parham
Journal:  Immun Inflamm Dis       Date:  2017-07-06

10.  Role of KIR3DS1 in human diseases.

Authors:  Christian Körner; Marcus Altfeld
Journal:  Front Immunol       Date:  2012-11-01       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.